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Purpose: Thrombosis after arterial injury is often initiated by von Willebrand factor 
(vWF)-dependent platelet accumulation. A promising antithrombotic strategy is the 
interruption of platelet/vWF interactions. Previously, we demonstrated how chemical 
and affinity modification can enhance heparin's anti-vWF activity while reducing conven- 
tional anticoagulation. Here, we investigated whether a modified heparin can block 
platelet-dominated arterial thrombosis. 
Methods: Standard heparin was oxidized with periodate, refined to have high vWF affinity 
and inhibitory potency, and tested in a guinea pig model of platelet-dependent arterial 
thrombosis. In this model, a controlled mechanical arterial injury yields cyclic flow 
variations (CFVs) caused by recurrent accumulation of platelet thrombi. 
Results: All six control animals developed CFVs (mean, 10.4 -+ 2.6 CFVs), and six of 
seven animals treated with standard heparin also developed CFVs (mean, 7.6 ± 4.6). 
Only one of six animals ta:eated with the anti-vWF heparin and one of six treated with 
AJvW-2 (an anti-vWF antiboäy) developed CFVs (mean, 2.0 -+ 4.9 and 0.5 + 1.2, 
respectively). Thus both the modified heparin and AJvW-2 were more effective than 
standard heparin (p < 0.03). Bleeding times and platelet counts were unaffected. A 
modified activated partial thromboplastin time was less prolonged by the modified 
high-affinity heparin (91 -+ 17 seconds) than by standard heparin (144 + 30 seconds; p < 
O.Ol). 
Conclusions: The modified heparin with high vWF affinity was a more effective arterial 
antithrombotic agent, with fewer conventional nticoagulant effects than standard hepa- 
rin. Interruption of the vWF/platelet interaction is a promising antithrombotic strategy 
that may be met by novel heparin-based antithrombotic drugs. (J Vasc Surg 1997; 
26:366-72. 
Platelet intcracnon with the injured blood vessel 
wall is one of the initial events of thrombosis. 1 von 
Willebrand factor (vWF) plays a major role in these 
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early phases ofplatelet deposition and adhesion. The 
platelet glycoprotein Ib (GpIb) receptor binds vWF 
and mediates the deposition of platelets on exposed 
surfaces, especially at areas of high shear stress. >6 
Ruggeri and others 7,8 have suggested that inhibi- 
tion of  the vWF/GpIb  interaction may be an effec- 
tive antithrombotic strategy. Antibodies to vWF 9 
and GpIb, l° as well as recombinant fragments of  
the vWF GpIb binding dom ain, 11 have been 
shown to have antithrombotic properties in animal 
models. 
In past work, we have shown that standard hepa- 
rin does inhibit vWF/platelet interactions in vitro 
and in vivo. 12 We localized an important heparin 
binding domain ofvWF 13 and characterized some of 
the structural aspects of heparin responsible for this 
activity. 14 Using a synthetic peptide based on this key 
heparin-binding domain of vWF, we used affinity 
fractionation to refine heparins to have enhanced 
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ability to inhibit vWF/platelet interactions. ~5 Chem- 
ical modification with periodate oxidation was used 
to reduce conventional anticoagulant activity medi- 
ated by antithrombin III. is 
To determine whether such a modified heparin 
could be an effective antithrombotic agent for plate- 
let-dominated arterial thrombosis, we tested a high 
vWF affinity heparin fraction in an in vivo guinea pig 
model? 6 In this model, a controlled mechanical in- 
jury to the carotid artery generates cyclic flow 
variations (CFVs) caused by recurrent platelet 
thrombi (similar to the Folts model of coronary 
artery occlusion). 17 Animals treated with standard 
heparin, modified high-affinity heparin, and a 
monoclonal antibody to vWF (AJvW-2) were 
tested for their effects on the development of re- 
current platelet hrombi (CFVs), as well as their 
effects on standard measures of plasma anticoagu- 
lation and hemostatic function. 
METHODS 
Reagents. The following materials were pur- 
chased: porcine mucosal heparin (179 anti-Xa units/ 
mg; molecular weight 13,500) from Celsus Co. 
(Cincinnati), ristocetin from Biodata Corp. (Hat- 
boro, Pa.), and activated partial thromboplastin time 
(aPTT) reagent (rabbit brain phospholipid with sil- 
ica) and calcium chloride from Organon Teknika 
(Durham, N.C.); the remaining reagents were ob- 
tained from Sigma Chemical Co. (St. Louis). 
Murine anti-human vWF monoclonal antibody, 
AJvW-2, was generously supplied by Dr. Ryota 
Yoshimoto of Ajinomoto Co., Inc. (Yokohama, Ja- 
pan). This antibody was established by standard hy- 
bridoma techniques and has been shown to inhibit in 
vitro ristocetin- and botrocetin-induced platelet ag- 
gregation in both human beings mid guinea pigs. 9 
Also, this antibody has been shown to inhibit throm- 
bosis in an in vivo guinea pig model of photochemi- 
cally-induced thrombosis. 9 
Animal model of  arterial thrombosis. Male 
guinea pigs (0.50 to 0.65 kg) were purchased from 
Hilltop Laboratories (Scottdale, Pa.). Animals were 
anesthetized with intraperitoneal pentobarbital. At 
the end of each experiment, he animals were killed 
with an intravenous overdose of pentobarbital. The 
skin over the neck area to be incised was infiltrated 
subcutaneously with 2% lidocaine to provide local 
anesthesia. One jugular vein was cannulated for drug 
administration, and one carotid artery was cannu- 
lated for blood sampling. Animal care complied with 
the "Principles of Laboratory Animal Care" of the 
National Society for Medical Research and the Guide 
for the Care and Use of Laboratory Animals of the 
National Institutes of Health. 
The arterial injury model is based on that de- 
scribed by Roux et al36 and Carteaux et al. 18 in 
which mechanical injury to the carotid artery is in- 
duced by pinching the vessel with a small forceps. 
Roux et al. 16 showed histologically that this gener- 
ates a platelet-rich thrombus that leads to vessel oc- 
clusion (similar to the Folts dog coronary artery 
model). 17 In our experience, this occlusion does not 
occur without he vessel injury. Gentle shaking of the 
carotid artery dislodges the platelet hrombus, and 
blood flow is restored Until 'the platelet hrombus 
reaccumulates, occluding flow and leading to repro- 
ducible CFVs. The mechanical shaldng was per- 
formed as follows: when the blood flow was reduced 
to less than 1 ml/min, tissue adjacent to the artery 
was grasped with small forceps and gently agitated 
for 2 to 3 seconds. After flow was reestablished, the 
shaking was repeated until there was no further in- 
crease in blood flow. If no flow was reestablished 
after repeating the shaking more than five times, the 
artery was considered permanently thrombosed. 
In these experiments, either buffered saline solu- 
tion or a test drug was administered at the doses 
described below. After the initial bolus, the carotid 
artery was injured approximately 3 mm proximal to 
an ultrasonic flow probe (Model 1R, Transonic Sys- 
tems, Inc., Ithaca, N.Y.) by three pinches of 1 second 
duration with a small forceps, spaced 5 minutes 
apart. The forceps were smooth surfaced, with a 
width of 1 ram. The handles were marked so that the 
forceps were closed to the same distance each time, 
enough to completely occlude the vessel. The CFVs 
generated were monitored and recorded with the 
ultrasonic flow probe using Flowtrac software (Tran- 
sonic Systems, Inc., Ithaca, N.Y.). Two parameters 
were measured: the number of animals developing 
CFVs and the number of CFVs generated over a 
50-minute observation period. 
Heparins and heparin dosing. Modified high 
vWF affinity heparin was prepared as described? s 
Briefly, standard heparin was treated with periodate 
oxidation to diminish its anti-Xa anticoagulant activ- 
ity; then it was refined by affinity chromatography to 
extract hose heparins with a high affinity for vWF. 
This was done using a Sepharose matrix coupled to a 
synthetic peptide containing the heparin-binding do- 
main ofvWF33 This refined heparin has a peak mo- 
lecular weight of I0,600 and only 6 U /mg of 
anti-Xa activity. Its aPTT activity was 7% of that of 
the standard heparin. Its ability to inhibit vWF/  
platelet interactions (as measured by in vitro inhibi- 
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Fig. 1. Carotid artery blood flow pattern after injury and 
treatment with saline solution. Flow was measured by 
Doppler probe and plotted at 10-second intervals. 
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Fig. 2. Carotid artery blood flow pattern after injury and 
treatment with standard heparin. Flow was measured by 
Doppler probe and plotted at 10-second intervals. 
Table I. CFV data for guinea pigs subjected to carotid artel3~ injury and treated with saline solution 
(control), standard heparin, AJvW-2, or modified high vWF affinity heparin 
Treatment Weight Blood flow a~ Number with Mean number 
group n (kg) start (tal/min) inhibition of CFVs of CFVs 
Control 6 0.58 _+ 0.05 12.3 _+ 3.9 0 /6  10.4 _+ 2.6 
Standard heparin 7 0.58 _+ 0.04 13.7 _+ 4.5 1/7 7.6 _+ 4.6 
AJvW-2 ó 0.62 ± 0.05 12.8 _+ 3.3 5/6  0.5 _+ 1.2 
High affinity heparin 6 0.55 ± 0.03 14.0 _+ 3.0 5/6  2.0 -- 4.9 
NS NS p < 0.03* p < 0.05]" 
(ANOVA) (ANOVA) (Fisher exact) (ANOVA) 
Data are presented as mean ± standard eviation. NS, Data were not significantly different in any of the groups. ANOVA, Analysis of 
variance. 
*p < 0.03 for the following pairs ofgroups: control vs high atfinity heparin; control vs AJvW-2; standard heparin vs high affinity heparin; 
and standard heparin vs AJvW-2. Other pairwise comparisons showed no significant differences. 
].p < 0.05 for the following pairs of groups: controi vs high atfinity heparin; control vs AJvW-2; standard heparin vs high atfinity heparin; 
and standard heparin vs AJvW-2. Other pairwise comparisons showed no significant differences. 
tion ofristoceun-induced platelet aggluunation) was 
approximately double that of the standard heparin. 
In these experiments, standard heparin was given 
at a dose of 54 anti-Xa U /kg  followed by a continu- 
ous infusion of  54 U /kg /hr  for 50 minutes, given by 
a 12000 Varioperpex peristaltic pump (LKB Instru- 
ments, Rockville, Mal.; n = 7). The modified heparin 
was given at a dose equivalent o one-third the 
anti-Xa activity of the standard heparin (18 anti-Xa 
U /kg  followed by a continuous infusion of 18 U /  
kg/hr; n = 6). The antibody AJvW-2 was given as a 
bolus of 200 Ixg/kg (n = 6). For control animals 
(n = 6), saline solution was given at the same infu- 
sion rate as the heparin groups, and the standard 
injury was induced. 
Hemostat ic testing o f  blood samples. Unless 
otherwisc noted, all blood samples were taken 
through the carotid artery sampling cannula into 
sodium citrate (find concentration, 0.38%). Platelet- 
poor plasma was obtained by centrifugation at1200B 
for 20 minutes. Platelet-rich plasma (PRP) was ob- 
tained by ccntrifugation at 160B for 10 minutes. 
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Fig. 3. Carotid artcry blood flow pattern after injury and 
treatment with modified high vWF affinity heparin. Flow 
was measured by Doppler probe and plotted at 10-second 
intervals. 
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Fig. 4. Carotid artery blood flow pattern after injury and 
trcatment with vVffF antibody AJvW-2. Flow was measured 
by Doppler probe and plotted at 10-second intervals. 
The aPTTs were determined by Fibrometer (Bec- 
ton Dicldnson, Cockeysville, Md.) at the end of the 
50-minute study period. Because values for animals 
treated with standard heparin were greater than 400 
seconds, aPTTs were also determined after diluting 
the sämples l : l  with normal pooled guinea pig 
plasma, based on the method escribed by Marder 19 
for plasma with high heparin content. The concen- 
tration of aPTT units was estimated with a standard 
curve created using heparin with a defined aPTT 
activity. 
The bleeding time was measured as described by 
Becker and Miller 2° for the guinea pig. Briefly, a 
small cuffwas applied to the upper thigh and inflated 
to a pressure of 40 mm Hg. After 30 seconds, an 
incision was made on the ventral aspect of the thigh 
using a Simplate R template device (Organon 
Teknika, Durham, N.C.), and blood was blotted 
with filter paper every 30 seconds until the bleeding 
stoppe& All tests were performed in duplicate. 
Platelet counts were obtained from PRP using a 
Coulter counter (Model Z F, Coulter Electronics, Hi- 
aleah, Fla.). 
vWF-dependent platelet aggregation. To 
show that the in vivo results could be explalned by 
the effects of the heparins on vWF acnvity, the test 
heparins were also added to guinea pig PRP, which 
Table II. aPTTs for guinea pig plasma fter 
treatment with saline solution (control), 
standard heparin, AJvW-2, or modified high 
vWF affmity heparin 
Treatment group aPTT (sec) Diluted aPTT (sec) 
Control (n = 6) 44 + 4 N /A  
Standard heparin (n = 7) >400 149 _+ 34* 
AJvW:2 (n = 6) 40 _+ 5 N /A  
High atfinity heparin 217 _+ 75 91 _+ 18" 
(n = 6) 
Data are presented as mean _+ standard eviation. Diluted aPTT 
refers to plasma diluted 1:1 with normal pooled guinea pig plasma. 
*p < 0.01, Student's t test. 
was then tested for ristocetin-induced platelet aggre- 
gätion. Ristocetin-induced aggregation has been 
shown to depend exclusively on the vWF/platelet 
GPIb interaction. 21,22 
Citrated blood was collected from four normal 
guinea pigs by cardiac puncture. PRP was prepared 
to a platelet count of 400,000/~1, and aggregation 
was measured in a Scienco (Morrison, Colo.) aggre- 
gometer. The heparins were added to the PRP at 
final concentrations equivalent to those determined 
to be present at the end of the CFV experiments (1.4 
aPTT U /ml  modified heparin and 2.1 aPTT U /ml  
standard heparin). Ristocetin was then added and 
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Table II I .  Platelet counts and bleeding times for guinea pigs trcated with saline solution (control), 
standard heparin, A]vW-2, or modified high vWF affinity heparin 
Pretreatment Posttreatment Posttreatment 
Treatment group platelet count/txl platelet count/txl bleeding time (sec) 
Control (n = 4) 403,000 _+ 8000 388,000 -+ 13,000 208 _+ 78 
Standard heparin (n = 4) 400,000 -+ 48,000 385,000 ± 6000 233 -+ 47 
AJvW-2 (n = 4) 397,000 - 15,000 391,000 -+ 30,000 233 -+ 70 
High atfinity heparin (n = 4) 395,000 _+ 31,000 380,000 ± 45,000 251 ± 45 
NS NS NS 
Data are presented as mean + standard eviation. NS, Data were not significantly different by analysis ofvariance. 
aggregation monitored by the change in light trans- 
mission. The amount of ristoeetin added was the 
minimum required to cause consistent aggregation 
in eontrol PRP for eaeh individual guinea pig (range, 
1.7 to 2.1 mg/ml).  
Statistical analysis. M1 values are reported as 
the mean +_ standard eviation. Analysis was per- 
formed using Sigmastat software. Fisher's exact est, 
X 2, analysis ofvariance, or Student's t test were used, 
as noted. 
RESULTS 
CFVs. Table I summarizes the CFV data from 
the four groups. The mean animal weight and start- 
ing blood flow were not significantly different in any 
of the treatment groups. All six saline solution- 
treated control animals developed CFVs that per- 
sisted throughout the observafion period. However, 
in one animal flow reduction was irreversible. A typ- 
ical blood flow pattern for the control animals is 
shown in Fig. 1. CFVs also developed in six of seven 
animals treated with standard heparin (Fig. 2). No 
CFVs at all were observed in five of six animals 
treated with modified heparin (Fig. 3). No CFVs 
were observed in five of the six animals treated with 
the antibody AJvW-2 (Fig. 4). The modified heparin 
and A~[vW-2 groups had fewer animals develop CFVs 
(p < 0.03, Fischer's exact test) than the control or 
standard heparin groups. 
For saline solution control animals, the mean 
number of CFVs over the 50 minutes was 10.4 _+ 
2.6. The single animal whose carotid artery became 
irreversibly occluded was excluded from this average. 
For standard heparin-treated animals, the mean 
number of CFVs was 7.6 -+ 4.6; for animals treated 
with modified heparin, 2.0 _+ 4.9; for AJvW-2 
treated änimals, 0.5 + 1.2. The modified heparin 
and AJvW-2 groups had fewer CFVs than the control 
and standard heparin groups (p < 0.05, analysis of 
variance). There was no significant difference be- 
tween the modified heparin and MvW-2 groups. 
Although the standard heparin group had a lower 
mean number of CFVs than the saline solution con- 
trol group, this ditkèrence was not significant. 
aPTTs. Both standard heparin and modified 
heparin prolonged the aPTT at the doses given (Ta- 
bie II), but all animals in the standard heparin group 
had aPTTs greater than 400 seconds, whereas the 
mean aPTT of the modified heparin-treated animals 
was 217 _+ 75 seconds. Treatment with AJvW-2 did 
not prolong the aPTT. To bring the values in the 
standard heparin group into a readable range, plasma 
samples were also tested for aPTT after dilution 1:1 
with pooled normal guinea pig plasma (Table II). 
The mean diluted aPTT of the standard heparin 
group was 149 + 34 seconds, whereas that of the 
modified heparin group was 91 + 18 seconds (p < 
0.01, Student's t test). Thus, by both nondiluted 
and diluted aPTT measurement methods, at these 
doses the modified heparin had significäntly less 
effect on the aPTT than the standard heparin. To 
estimate the conventional nticoagulant activity of 
the plasma samples, a standard aPTT curve was 
constructed using a heparin with a defined activity 
of 180 aPTT U /mg.  Using this curve, the antico- 
agulant concentration of modified heparin in the 
plasma samples was 1.4 aPTT U /ml ,  and the con- 
centration of standard heparin in the samples was 
2.1 aPTT U/ml .  
Bleeding times and platelet counts. None of 
the treatments significantly prolonged the bleeding 
time compared with control animals (Table III). For 
all the groups, the platelet counts at the end of the 
observation period »vere not significantly different 
(Table III). 
vWF-dependent platelet aggregation. At the 
plasma concentrations of the heparins present at the 
end of the study period, the modified heparin com- 
pletely inhibited ristocetin-induced platelet aggrega- 
tion in PRP from all four guinea pigs teste& The 
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experimental dose of standard heparin was unable to 
inhibit aggregation i any of the guinea pigs. 
D ISCUSS lON 
The purpose of this study was to determine 
whether a heparin could be modified to achieve a 
more specific, focused antithrombofic effect, namely 
to inhibit platelet-dependent thrombosis with re- 
duced conventional anticoagulafion effects. The 
pathophysiologic mechanism of the induced arterial 
injury model is supported by the antecedent work of 
Folts, 17 who showed that the mechanism of the 
CFVs observed at sites of arterial injury is the gener- 
ation of recurrent platelet hrombi. The relevance in 
this guinea pig model has been further confirmed by 
Roux et al., ló who documented the presence of 
platelet-rich thrombi histologically. Finally, our own 
studies using a monoclonal anti-vWF antibody, 
AJvW-2, have confirmed the critical importance of 
the platelet/vWF adhesive interaction at sites of in- 
duced arterial injury; the vWF-blocldng antibody in- 
hibited CFVs without any other effects on coagula- 
tion. Other strategies to inhibit the vWF/platelet 
GpIb receptor interaction have been invesfigated, 
including the use ofantibodies to GpIb ~° and recom- 
binant fragments of vWF. ~ 1 
Here, we observed that a modified heparin, 
which previously has been shown to have enhanced 
anti-vWF activity in vitro, can inhibit the develop- 
ment of CFVs in vivo better than standard heparin, 
in spite of its diminished effect on the aPTT. The in 
vivo doses used in this study also inhibited ristocetin- 
induced platelet aggregation i vitro. Thus the mod- 
ified heparin is a better antithrombotic agent than 
standard heparin at sites of arterial injury, at doses 
that cause less effect on the coagulation cascade. 
One concern with inhibiting vWF activity is that 
bleeding time may be prolonged, leading to a hem- 
orrhagic tendency (as in von Willebrand disease). 
However, in these experiments, the bleeding time 
and platelet count were unaffected by treatment with 
AJvW-2 or with the modified, high vWF affinity 
heparin, even at a dose that completely inhibits in 
vitro vWF-dependent platelet aggregation. The lack 
of effect on bleeding time after treatment with the 
antibody AJvW-2 has been observed in the past. 9 
Using recombinant fragments of vWF's GpIb bind- 
ing domain and antibodies to platelet GpIb recep- 
to rs ,  2° other investigators have also confirmed this 
finding--effecfive pharmacologic blockage of vWF 
does not necessarily induce a prolongation of the 
bleeding time. This suggests that the hemostatic de- 
rangement caused by von Willebrand disease (in 
which the bleeding fime is prolonged) is more com- 
plex than a simple drug-induced blockade of the 
vWF/platelet GpIb interaction. 
In the present study, the guinea pig was chosen 
because the model would be homologous to human 
hemostasis. Guinea pig platelet receptors have been 
found to be very similar to human platelet GP I Ib /  
IIIa and GpIb/ IX,  23,24 and their platelet function is 
similar in regard to adenosine diphosphate r sponse, 
the arachidonic acid cascade, and vWF. 24,25 Also, the 
shear rate in the guinea pig carotid artery is high 
(approximately 2000 seconds 1), where vWF is most 
important for platelet deposition at sites ofinjury. 4,26 
Inhibition ofvWF/platelet interacfions with a mod- 
ified heparin may not be as effective at lower shear 
rates, such as those seen in larger arteries or veins. 
However, at stenosed arteries and in smaller arteries 
where shear rate is higher, such a drug would offer 
more specific and effective anfithrombotic action. 
These experiments have demonstrated that affin- 
ity refinement of a heparin to enhance its ability to 
inhibit vWF/platelet interactions, combined with 
chemical modificafion to diminish its convenfional 
anticoagulant activity, enables it to inhibit platelet- 
rich thrombus formation at sites of arterial injury 
bettet han standard heparin, vdth less prolongation 
of the aPTT and no prolongation of the bleeding 
time. These results were comparable with those ob- 
tained with the anti-vWF monoclonal antibody, 
AJvW-2. These studies offer hope for the develop- 
ment of a new family of heparin-based agents with 
selective activity: enhanced anfithrombofic activity 
with reduced risk of the hemorrhagic complications 
associated with conventional anticoagulafion. By 
blocldng the very inifial stages of platelet accumula- 
tion, it may be possible to interrupt many of the 
subsequent pathologic events associated with plate- 
let-vessel wall interactions. 
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